Breaking News

Dollar Tree Agrees to Buy Family Dollar for $74.50 a Share
Tweet TWEET

InterMune Announces Support of The Pulmonary Fibrosis Foundation Care Center Network and Patient Registry Initiative

 InterMune Announces Support of The Pulmonary Fibrosis Foundation Care Center
                   Network and Patient Registry Initiative

- Largest multi-center registry in world to advance understanding of pulmonary
fibrosis -

PR Newswire

BRISBANE, Calif., Dec. 10, 2013

BRISBANE, Calif., Dec. 10, 2013 /PRNewswire/ -- InterMune (NASDAQ: ITMN)today
announced its support of the Pulmonary Fibrosis Foundation, a leading patient
advocacy organization dedicated to advancing care for people with pulmonary
fibrosis worldwide, to establish the Pulmonary Fibrosis Foundation Care Center
Network and Patient Registry. The Care Center Network will launch in 2014
with nine prestigious academic medical centers implementing a care center
model combining high-quality patient care with clinical research to collect
essential information from patients to build the Registry. This major
initiative will be critical to improving the understanding of pulmonary
fibrosis – a disease characterized by the decline of lung function – and will
facilitate early diagnoses; provide quality, standardized care; expedite
enrollment in clinical trials and enhance support services.

(Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said,
"InterMune has spent more than a decade committed to advancing the science of
idiopathic pulmonary fibrosis (IPF) – the most prevalent form of pulmonary
fibrosis. As part of our ongoing commitment, we are proud to support the
Pulmonary Fibrosis Foundation to establish its Care Center Network and Patient
Registry. InterMune's vision is to alter the course of IPF – a challenging
and deadly disease – through the development of new therapies that can provide
hope to patients and their families. We believe this work the Foundation is
undertaking is a significant step towards benefiting the IPF community."

This project will eventually become the largest multi-center PF registry in
the world. The nine pilot centers include: The University of California San
Francisco, The University of Washington in Seattle, Wash., Yale University,
Vanderbilt University, The University of Chicago, The University of
Pittsburgh, The University of Michigan, The University of Louisville and
National Jewish Health in Denver, Colo. Additional centers will be added each
year.

"Establishing a patient registry for pulmonary fibrosis is a major milestone
for this community," said Daniel M. Rose, M.D., Chief Executive Officer and
Chairman of the Board of Directors of the Pulmonary Fibrosis Foundation.
"While we have made important strides in understanding this illness, the
Pulmonary Fibrosis Foundation Care Center Network and Patient Registry will
increase the volume and consistency of high-quality data that will fuel our
progress. It will enable improvements in the health and quality of life for
patients and help generate insights so that the research community can come
closer to a cure. We thank InterMune for their support and their ongoing
dedication to the pulmonary fibrosis community."

About Pulmonary Fibrosis
Pulmonary fibrosis is a condition in which the lung tissue becomes thickened,
stiff, and scarred. The medical terminology used to describe this scar tissue
is fibrosis. As the lung tissue becomes more "fibrotic," it is more difficult
for the lungs to transfer oxygen into the bloodstream. In most cases, there
is no known cause for the development of pulmonary fibrosis. When the cause
is unknown, the disease is further characterized as idiopathic pulmonary
fibrosis, or IPF. The median survival time from diagnosis in IPF is two to
five years, with a five-year survival rate of approximately 20-40 percent,
which makes the disease more rapidly lethal than many cancers, including
breast, ovarian and colorectal. IPF typically occurs in patients over the age
of 50, and is more common in men than in women. IPF affects an estimated
50,000-70,000 people in the United States, and approximately 15,000-20,000 new
cases of IPF are diagnosed each year. 

About InterMune
InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and orphan fibrotic
diseases. In pulmonology, the company is focused on therapies for the
treatment of idiopathic pulmonary fibrosis (IPF), a progressive, irreversible,
unpredictable and ultimately fatal lung disease. Pirfenidone, the only
medicine approved for IPF anywhere in the world, is approved for marketing by
InterMune in the EU and Canada as Esbriet^® and is currently in a Phase 3
clinical trial to support regulatory registration in the United States.
InterMune's research programs are focused on the discovery of targeted,
small-molecule therapeutics and biomarkers to treat and monitor serious
pulmonary and fibrotic diseases.For additional information about InterMune
and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of
section 21E of the Securities Exchange Act of 1934, as amended, that reflect
InterMune's judgment and involve risks and uncertainties as of the date of
this release, including without limitation, InterMune's expectation regarding
the anticipated academic medical centers that will be a part of the Pulmonary
Fibrosis Foundation Care Center Network and Patient Registry initiative and
the timing of the launch thereof; the initiative being critical to improving
the understanding of pulmonary fibrosis, facilitating early diagnoses,
providing quality, standardized care, expediting enrollment in clinical trials
and enhancing support services; the work with the Pulmonary Fibrosis
Foundation being a significant step towards achieving InterMune's vision to
alter the course of IPF; the initiative increasing the volume and consistency
of data that will fuel InterMune's vision, enabling improvements in the health
and quality of life for patients and helping generate insights so that the
research community can come closer to a cure; the estimated number of people
in the United States that IPF affects and the estimated number of new cases of
IPF diagnosed each year. All forward-looking statements and other information
included in this press release are based on information available to InterMune
as of the date hereof, and InterMune assumes no obligation to update any such
forward-looking statements or information. InterMune's actual results could
differ materially from those described in InterMune's forward-looking
statements.

Other factors that could cause or contribute to such differences include, but
are not limited to, those discussed in detail under the heading "Risk Factors"
in InterMune's most recent annual report on Form 10-K filed with the
Securities and Exchange Commission (SEC) on March 1, 2013 (the "Form 10-K")
and other periodic reports filed with the SEC, including but not limited to
the following: (i) the risks related to the uncertain, lengthy and expensive
clinical development process for the company's product candidates, including
having no unexpected safety, toxicology, clinical or other issues and having
no unexpected clinical trial results such as unexpected new clinical data and
unexpected additional analysis of existing clinical data; (ii) risks related
to the regulatory process for the company's product candidates, including the
possibility that the results of InterMune's 52-week Phase 3 clinical trial
(ASCEND) having an FVC endpoint may not be satisfactory to the FDA for
InterMune to receive regulatory approval for pirfenidone in the United States;
and (iii) risks related to unexpected regulatory actions or delays or
government regulation generally. The risks and other factors discussed above
should be considered only in connection with the fully discussed risks and
other factors discussed in detail in the Form 10-K and InterMune's other
periodic reports filed with the SEC, including its Quarterly Report on Form
10-Q for the quarterly period ended September 30, 2013, all of which are
available via InterMune's web site at www.intermune.com.

SOURCE InterMune, Inc.

Website: http://www.intermune.com
Contact: Jim Goff, InterMune, Inc., 415-466-2228, jgoff@intermune.com